drugset / Trial / NCT07477912
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Phase 1/2
Recruiting
30 enrolled
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
NaSingle-groupOpen-labelTreatment
Summary
The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma
Timeline
- Start
- 2025-02-01
- Primary completion
- 2028-02-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-BCMA CAR T cells | Cell therapy | 5e+07 cells | — |
| Subject | Anti-BCMA CAR T cells | Cell therapy | 2.5e+08 cells | — |